Eli Lilly’s experimental drug lowers risk of heart disease by 94%: study – New York Post

1. Eli Lilly’s experimental drug lowers risk of heart disease by 94%: study New York Post
2. Eli Lilly’s Heart Drug Lepodisiran Cuts Lipoprotein Lp(a) for Year in Study Bloomberg
3. Trial Shows a Single Dose of an Experimental Therapy Reduces Lipoprotein(a), an Important Heart Disease Risk Factor, More than 94% for Nearly a Year Cleveland Clinic Newsroom
4. Sustained Reductions in Lp(a) Achieved With Novel siRNA Drug Medscape
5. One dose of experimental therapy reduced lipoprotein(a) more than 94% for nearly a year American Heart Association
6. View Full Coverage on Google News

Read original article here